Latest News and Press Releases

Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in 6MWD, cardiac effort and QoL.

Liquidia and Pharmosa announced they have amended the current exclusive licensing agreement for the development and commercialization of L606.

Liquidia Corporation announces raise of $67.5M.

Liquidia Corporation (LQDA) announced today that the company will present at two investor conferences this September.

The FDA has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with PAH and PH-ILD.

Judge Andrews denied the motion for preliminary injunction filed by United Therapeutics that sought to block the launch of Liquidia’s YUTREPIA™.

Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the first quarter ended March 31, 2024.